Real-world time on treatment with immuno-oncology therapy in recurrent/metastatic head and neck squamous cell carcinoma
- Resource Type
- Authors
- Zhiwen Liu; Diana Chirovsky; Shrujal S. Baxi; Karthik Ramakrishnan; Sam Joo; Sheenu Chandwani
- Source
- Future Oncology. 17:3037-3050
- Subject
- Male
Time on treatment
Oncology
Cancer Research
medicine.medical_specialty
Time Factors
Carboplatin
03 medical and health sciences
Antineoplastic Agents, Immunological
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
medicine
Humans
030212 general & internal medicine
Aged
Retrospective Studies
Adult patients
Squamous Cell Carcinoma of Head and Neck
business.industry
Electronic medical record
General Medicine
Middle Aged
medicine.disease
Head and neck squamous-cell carcinoma
Progression-Free Survival
Clinical trial
Head and Neck Neoplasms
030220 oncology & carcinogenesis
Female
Cisplatin
Neoplasm Recurrence, Local
Previously treated
business
- Language
- ISSN
- 1744-8301
1479-6694
Aim: We report real-world time on treatment (rwToT) with immuno-oncology (I-O) and other systemic therapies in second-line recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) previously treated with platinum therapies. Materials & methods: Adult patients receiving first-line platinum therapy for R/M HNSCC between January 2017 and December 2018 and a second-line therapy were selected from a US electronic medical record database. Results: In our study sample of 619 R/M HNSCC patients, second-line treatments primarily included I-O therapies (71%) and resulted in median rwToT of 2.8 months and 12-month on-treatment rate of 19.3%. For other second-line therapies, median rwToT and 12-month on-treatment rate was 1.9 months and 1.3%, respectively. Conclusion: Use of second-line I-O therapies was common and resulted in rwToT consistent with R/M HNSCC clinical trials.